Monte Rosa Therapeutics (GLUE) Profit After Tax (QoQ) (2020 - 2026)

Monte Rosa Therapeutics (GLUE) Profit After Tax (QoQ) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Monte Rosa Therapeutics 2.29 Bn 1.61 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 1.49%
Dec 31, 2025 -70.26%
Sep 30, 2025 -120.26%
Jun 30, 2025 -126.21%
Mar 31, 2025 278.23%
Dec 31, 2024 151.98%
Sep 30, 2024 21.28%
Jun 30, 2024 5.19%
Mar 31, 2024 4.85%
Dec 31, 2023 3.18%
Sep 30, 2023 1.36%
Jun 30, 2023 -9.80%
Mar 31, 2023 -6.09%
Dec 31, 2022 -10.55%
Sep 30, 2022 -3.21%
Jun 30, 2022 -10.60%
Mar 31, 2022 -1.92%
Dec 31, 2021 -18.37%
Sep 30, 2021 -7.78%
Jun 30, 2021 -49.93%